Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2018

View Archived Issues

LogicBio Therapeutics begins program for genome-editing therapy for methylmalonic acidemia

CFDA clears HG-146 to enter clinical trials for multiple myeloma

Intrommune Therapeutics launches financing campaign to support development of INT-301

Shionogi recaps progress of fourth quarter of fiscal 2017

SPRINT-MS trial: phase II results of ibudilast treatment in progressive multiple sclerosis

EVOLVE-MS-1 trial shows ALKS-8700 effects in patients with relapsing remitting multiple sclerosis

First patient dosed in the phase I/II trial of KB-103

Promising in vivo results for EP-055, a potential nonhormonal male contraceptive

Mainline Biosciences submits pre-IND meeting information package for MLB-1707

ROCK and PKC inhibitor AR-13503 in development for ocular disorders

Novel liver X receptor beta agonists divulged by Merck & Co.

Nimbus Lakshmi patents novel TYK2 inhibitors

Lundbeck identifies novel phosphodiesterase PDE1 inhibitors

Positive topline data from phase I trial of prophylactic CMV vaccine candidate VBI-1501

Novel P2X purinoceptor 7 antagonists discovered at Shionogi

Prelude Therapeutics discovers PRMT5 inhibitors

Patient recruitment ongoing in phase I trial of PF-06821497

Novel PTP-2C inhibitors discovered at DE Shaw Research, Relay Therapeutics

Pharmasum Therapeutics identifies novel DYRK inhibitors

MFN2 agonist restores mitochondrial trafficking in models of Charcot-Marie-Tooth disease type 2A

Phosphodiesterase PDE4 inhibitors patented byTakeda

Lilly to acquire ARMO BioSciences

FDA identifies deficiencies during NDA review of Methylene Blue MMX

Phase I study of AVB-S6-500 demonstrates proof of mechanism

Researchers present nanoencapsulated hepatocyte enzymes to fight alcohol intoxication

SymBio enters joint research agreement with Keio University to evaluate Treakisym for SLE

CARB-X supports Talis' development of diagnostics to detect chlamydia and gonorrhea

KemPharm reports topline data from human abuse potential trial with KP-415 prodrug

FDA advisory committee votes in favor of Waylivra for familial chylomicronemia syndrome

Phase III GALATHEA trial of Fasenra in COPD does not meet primary endpoint

Lipimetix sublicenses Apo E mimetic peptide platform to Anji

New phase II proof-of-concept trial studies IXT-m200 in methamphetamine users

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...